Chi's questions to GALAPAGOS (GLPG) leadership • Q1 2024
Question
Asked two questions about the immunology pipeline: one on the R&D strategy for CAR-T in autoimmune diseases beyond lupus, and another on the potential for expanding the TYK2 inhibitor (3667) into new indications like uveitis.
Answer
For the TYK2 inhibitor, the company is focused on delivering proof-of-concept results in lupus and dermatomyositis before considering expansion into other indications. For autoimmune CAR-T, they are actively exploring new non-viral vector technologies through internal R&D and external collaborations.